3D bioprinting harnesses the power of additive manufacturing, allowing researchers to spatially arrange various cell types and extracellular matrix components with remarkable accuracy. This innovation ensures that printed melanoma models more faithfully mirror the cellular heterogeneity and complex architecture of native human skin. By integrating multiple bioinks, each designed to emulate different aspects of skin biology, these bioprinted constructs achieve remarkable biomimicry. This approach provides a critical advantage over previous models by incorporating vascular-like structures and even elements of immune system components—features that are pivotal in modulating tumor behavior and therapeutic responses.

One of the most compelling applications of these 3D bioprinted melanoma models lies in their utility for assessing anticancer strategies that combine photodynamic therapy (PDT) with cutting-edge drug delivery systems. PDT, a treatment involving the activation of photosensitizers by specific wavelengths of light to produce cytotoxic reactive oxygen species, has shown potential against melanoma cells. However, its efficacy can be limited by challenges such as inadequate photosensitizer delivery and poor penetration of activating light into tumor tissues. Here, nanocarrier-based drug delivery systems meticulously engineered for targeted and controlled release come into play, optimizing the therapeutic payload delivered to tumor sites while minimizing off-target effects.

The synergy between PDT and advanced drug delivery vehicles can be methodically explored using 3D bioprinted models that recreate the tumor microenvironment, including barriers to drug and light penetration. This represents a significant leap over conventional culture systems, where the lack of realistic skin architecture hinders accurate prediction of therapeutic outcomes. Moreover, the tunable nature of bioprinting permits the fabrication of melanoma constructs with varying degrees of complexity and cell composition, thereby facilitating the screening of personalized treatment regimens and the examination of tumor heterogeneity.

Bioink formulation remains a crucial aspect of this field, demanding materials that support cell viability, encourage appropriate cell signaling, and replicate the mechanical properties of native skin. Researchers have been developing composite bioinks combining natural polymers such as collagen and hyaluronic acid with synthetic components to fine-tune printability and structural stability. These advancements permit the generation of melanoma models that not only survive the printing process but also exhibit functional characteristics like proliferation, migration, and invasion of melanoma cells within a matrix that simulates the skin extracellular matrix.

The dynamic interaction between melanoma cells and other skin-resident cells, such as fibroblasts, endothelial cells, and immune cells, can be faithfully studied within these bioprinted constructs. Recreating the intricate crosstalk and signaling within this microenvironment is critical for understanding treatment resistance mechanisms and tumor progression pathways. For example, incorporating endothelial cells can induce vascular mimicry, allowing researchers to evaluate how drug carriers and photosensitizers distribute within tumoral and peri-tumoral areas, thereby fine-tuning treatment parameters for maximal efficacy.

In addition to biological fidelity, 3D bioprinting streamlines reproducibility and scalability, which are essential for preclinical drug testing and regulatory approval processes. Unlike spontaneously formed spheroids or organoids, bioprinting provides consistent spatial cell patterning, ensuring that each sample is nearly identical in cellular composition and architecture. This reproducibility dramatically enhances the reliability of experimental results and enables high-throughput screening of drug candidates in complex tissue-like systems.

While this evolving technology is promising, challenges still remain, notably regarding the integration of fully functional immune components and the replication of the dynamic vascular networks observed in vivo. Future innovations might incorporate advanced biomaterials, vascularization techniques, and immune modulators to produce even more comprehensive melanoma models. Such advancements would provide an unparalleled platform for dissecting tumor immunology and for developing immunotherapeutic agents that complement PDT and nanocarrier-delivered drugs.

The combination of 3D bioprinted melanoma models with emerging therapeutic strategies underscores a paradigm shift in how anticancer drug screening and photodynamic therapy assessments are conducted. By bridging the gap between simplistic in vitro cultures and complex in vivo environments, these models promise to accelerate the pace of translational research, reduce reliance on animal testing, and ultimately improve clinical outcomes for patients with malignant melanoma.

In summary, the integration of bioprinting technology with melanoma research marks a formidable advance, offering robust platforms that recapitulate native skin conditions and tumor microenvironments with unprecedented precision. This enables a more insightful evaluation of contemporary anticancer strategies, combining photodynamic therapy with drug delivery systems tailored for superior targeting and efficacy. As these technologies mature, they have the potential to transform both experimental oncology and personalized medicine, providing new hope against one of the most lethal forms of skin cancer.

The ongoing evolution of melanoma modeling through 3D bioprinting invites a deeper exploration of tumor biology, therapeutic responsiveness, and drug delivery optimization. These advancements pave the way for definitive preclinical platforms that faithfully predict clinical outcomes, opening avenues for the development of novel combination therapies. Ultimately, the marriage of bioprinted skin constructs and state-of-the-art treatment modalities represents not only a technological breakthrough but also a beacon of hope in the fight against melanoma.

Subject of Research:
Article Title: 3D bioprinted melanoma models: a novel paradigm for the assessment of anticancer strategies combining PDT and drug delivery systems
Article References:
do Amaral, S.R., Atanasov, A.P., de Souza, D.C.M. et al. 3D bioprinted melanoma models: a novel paradigm for the assessment of anticancer strategies combining PDT and drug delivery systems. BioMed Eng OnLine 24, 132 (2025). https://doi.org/10.1186/s12938-025-01476-4
Image Credits: AI Generated
DOI: 10.1186/s12938-025-01476-4 (Published 06 November 2025)

Flaherty serves as the director of clinical cancer research at the Mass General Cancer Center, a leader in oncology, and holds the Richard Saltonstall Endowed Chair. He is also a professor of medicine at Harvard Medical School as well as an associate member of the Broad Institute of MIT and Harvard. His dual roles as a clinician and researcher allow him to bridge the gap between cutting-edge scientific research and its application in clinical settings.

His research has been notably focused on melanoma, where he has made crucial strides in understanding the molecular consequences of targeting oncogenic pathways. Flaherty has been at the forefront of developing innovative therapeutic approaches for melanoma, leading to groundbreaking enhancements in treatment options. His work has particularly emphasized the association between genetic characteristics of tumors and the efficacy of targeted therapies, bringing new hope to patients diagnosed with this aggressive form of skin cancer.

Flaherty’s groundbreaking contributions to the field are perhaps best exemplified by his pioneering work with vemurafenib—a revolutionary drug designed to target the BRAF V600E mutation, which occurs in a significant percentage of melanoma cases. The success of this therapy not only provided a new treatment avenue for patients but also established a model for future targeted therapies. His early clinical trials laid the groundwork for what would become a series of FDA-approved combination treatments that have transformed the therapeutic landscape for melanoma.

In addition to his research, Flaherty is deeply committed to mentorship and professional development within the scientific community. As AACR President-Elect, he aims to reinforce initiatives that cultivate a new generation of translational researchers. He recognizes the necessity of addressing health disparities in cancer treatment and is particularly focused on training scientists who are dedicated to serving underserved populations. His vision includes fostering collaboration across disciplines and ensuring that innovative cancer research translates into practice for all patients, regardless of their socio-economic background.

The AACR, with a membership exceeding 58,000 individuals from 141 countries, plays a crucial role in connecting professionals dedicated to cancer research. Under Flaherty’s proposed leadership, the organization is expected to enhance efforts in research funding, education, communication, and scientific advocacy. By aligning the AACR’s mission with advanced research initiatives, Flaherty hopes to stimulate further advancements in cancer prevention and therapy.

Margaret Foti, the CEO of the AACR, commended Flaherty’s dedication and exceptional service, predicting a thriving future for the organization under his leadership. She emphasized his remarkable achievements in targeted melanoma therapies and noted that his mentoring efforts have significantly influenced the next generation of cancer researchers. Her support of Flaherty’s presidency highlights the collective aspiration within the AACR community to continue breaking barriers in cancer research.

Flaherty’s history with AACR dates back to 2001, during which he has garnered respect and recognition, having been elected as a Fellow of the AACR Academy this past year. His service on the AACR Board of Directors, spanning from 2019 to 2022, demonstrates his active involvement in key decision-making processes and strategic planning within the organization. Currently, he serves on several committees, contributing his expertise to various initiatives aimed at healthcare advancement.

Flaherty’s influence is also evident in the structure and content of the AACR Annual Meetings. His leadership roles on the Annual Meeting Program Committee, including chair and cochair positions, reflect a commitment to fostering impactful discourse within the scientific community. Additionally, his participation in clinical trials committees further stresses his dedication to evaluating emerging cancer therapies.

Moreover, Flaherty has served as the editor-in-chief of the AACR journal Clinical Cancer Research, amplifying the visibility of critical research and fostering rigorous peer-reviewed scholarship. His editorial roles signify his dedication to ensuring the dissemination of cutting-edge research that informs both scientific and clinical practices related to cancer.

Beyond his editorial work, Flaherty’s accolades illustrate his significant standing in the oncology community. Recognized with the OncLive Giants of Cancer Care Award for his contributions to melanoma treatment, he has also received multiple high-profile awards, such as the Society for Melanoma Research Lifetime Achievement Award. Each recognition underscores his lasting impact on the field of cancer research, particularly in developing therapies that improve patient outcomes.

Academically, Flaherty’s foundation is rooted in rigorous training; he completed his undergraduate studies in neurobiology at Yale University and earned his medical degree from Johns Hopkins University. This educational background has informed his clinical practice and research pursuits, emphasizing both scientific inquiry and patient-centered care.

As Flaherty prepares to assume his role as President-Elect, the AACR anticipates his leadership will catalyze new advancements in cancer research and treatment. His vision revolves around integrating innovative scientific discoveries with clinical applications, ensuring that the most vulnerable populations receive the therapeutic benefits of ongoing research.

The election of Keith T. Flaherty as President-Elect of the AACR represents a promising step forward for the organization and the broader cancer research community. His leadership is poised to inspire ongoing collaboration, mentorship, and groundbreaking discovery essential for combating cancer in all its forms.

Subject of Research: Cancer Research
Article Title: AACR Elects Keith T. Flaherty as President-Elect for 2025-2026
News Publication Date: [Not provided]
Web References: [Not provided]
References: [Not provided]
Image Credits: [Not provided]

Keywords: Cancer research, AACR, Melanoma, Targeted therapies, Clinical trials, BRAF V600E mutation, Oncology, Translational research, Health disparities, Mentorship, Scientific community, Cancer treatment.

The research indicates that blocking MARCO alters the behavior of immune cells within the tumor microenvironment. This alteration results in an increased influx of immune cells, which subsequently augments the effectiveness of anti-CTLA4 treatments. This development is particularly significant for what are termed "cold" tumors—cancers that typically lack sufficient immune cell presence and often prove resistant to conventional immunotherapies. The findings suggest that targeting MARCO can help mobilize the immune system in a way that was previously unattainable for many patients suffering from these challenging tumor types.

James Mulé, who serves as the associate center director for Translational Science at Moffitt and leads the study, articulated the research’s implications by noting that targeting MARCO could bolster the efficacy of existing immunotherapeutic drugs without necessitating the depletion of macrophages. This finding not only introduces a new paradigm for treating melanoma but also lays the groundwork for broader application in various types of cancers, providing hope to those in need of innovative treatment options.

Investigators performed an experimental study utilizing animal models, wherein they introduced a monoclonal antibody aimed at MARCO, observing its effects when combined with anti-CTLA4 therapy. The results were striking: the combination treatment led to a substantial increase in immune cell infiltration within the tumor. Dendritic cells, which are instrumental in priming the immune response against tumors, showed particular enhancement in their numbers following the combination therapy, highlighting the synergistic potential of this new approach.

It is intriguing to note that this study specifically mentioned that similar improvements were not observed when anti-MARCO therapy was paired with anti-PD1 treatment. This distinction underscores the unique role MARCO plays in enhancing anti-CTLA4 efficacy. The researchers emphasize the necessity of further dissecting the underlying mechanisms at play to better understand the immunological dynamics following MARCO inhibition.

Furthermore, the study opens doors for clinical trials aimed at integrating MARCO-targeting strategies into both neoadjuvant and adjuvant therapy settings. By mitigating the chances of cancer recurrence through enhanced immune preparation within the tumor microenvironment, the findings could significantly reshape our approach to cancer prevention and treatment.

Publications such as these have essential implications not only for melanoma treatment but also for a multiplicity of cancers where current therapies fall short. This research underlines the importance of continual innovation in cancer treatment modalities, striving to provide more comprehensive care to patients.

The significance of this study cannot be overstated, as it brings to light the intricate interplay between immune cells and tumor cells and emphasizes the need for tailored therapies that resonate with the biology of the disease. As Moffitt Cancer Center continues to push the envelope in cancer research, this study represents a vital stepping stone toward more effective and personalized treatment options for patients battling cancer.

In conclusion, the targeting of MARCO presents a promising avenue for enhancing the efficacy of immunotherapy for melanoma and potentially other cancers. The implications of this research are profound, suggesting that a redefined approach to immuno-oncology could lead to substantial improvements in patient outcomes. These findings herald an exciting future in cancer therapy, where personalized medicine and innovative strategies converge for better patient care.

Subject of Research: Animals
Article Title: Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming
News Publication Date: March 13, 2025
Web References: Moffitt Cancer Center
References: Journal for ImmunoTherapy of Cancer
Image Credits: None provided
Keywords: Immunotherapy, melanoma, MARCO, anti-CTLA4, cancer research, immune cells, tumor microenvironment, clinical trials, personalized medicine.